Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis

FDA is encouraging sponsors to use data from an interim analysis of an ongoing pivotal trial to support accelerated approval of cancer products, rather than relying on separate postmarketing studies

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet